Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'

Novartis recently acquired Avidity Biosciences for $12 billion, its largest deal in a decade, to bolster its drug pipeline and counter generics competition, with CEO Vas Narasimhan emphasizing continuous M&A for growth. While the company reported a 7% constant currency sales increase and a 25% net income jump in Q3, the latter missed analyst expectations, and Novartis maintained its full-year guidance despite analyst hopes for an upgrade. The firm is also actively engaged in discussions with the U.S. administration regarding "most favored nation" drug pricing agreements, with Narasimhan indicating that while U.S. prices might modestly adjust, a lack of price increases in other developed markets could deter future drug launches there.

Analysis

Novartis (NVS) announced a strategic $12 billion acquisition of Avidity Biosciences (RNA), its largest in a decade, to bolster its pipeline with experimental drugs projected to generate billions by 2030. This M&A, supported by nearly $20 billion in annual free cash flow, aims to counter generics competition and drive future growth.

The company reported a 7% increase in Q3 constant currency sales to $13.9 billion, driven by strong growth in key drugs like Kisqali. However, net income of $3.9 billion, up 25% YoY, missed analyst consensus of $4.4 billion, and Novartis maintained its full-year guidance, disappointing expectations for an upgrade.

NVS shares fell 3.4% post-announcement, reflecting the net income miss and unchanged guidance, alongside headwinds from loss of exclusivity (-7 percentage points) and U.S. revenue deduction adjustments (-2 percentage points). Regulatory uncertainty persists from ongoing "most favored nation" (MFN) drug pricing discussions with the U.S. administration. CEO Narasimhan warned that while U.S. prices may adjust modestly, a lack of price increases in other developed nations could deter future drug launches there.

Key Decisions for Investors

• Investors should closely monitor the integration of Avidity Biosciences and the progress of its experimental drug pipeline, as its success is crucial for offsetting generic erosion and justifying the $12 billion acquisition.
• Evaluate future earnings reports for any deviation from the maintained guidance, especially considering the Q3 net income miss and the potential impact of MFN agreements on 2026+ earnings, as highlighted by UBS.
• Pay close attention to developments in U.S. drug pricing policies, particularly the outcome of Novartis's MFN discussions, and assess the potential implications for both U.S. and international market access and pricing strategies.